Roquefort Therapeutics to acquire Coiled Therapeutics in £30 million reverse takeover
LONDON: Roquefort Therapeutics plc (LSE:ROQ), a Main Market-listed biotech firm, said Monday it has entered into a binding term sheet to acquire Coiled Therapeutics, Inc., a clinical-stage oncology company spun out from A2A Pharmaceuticals, in a reverse takeover valued at £30 million. The deal, payable in shares, would give Roquefort full ownership of Coiled USA…